Types of Rosacea Explained: Subtypes, Symptoms, and What They Look Like

Rosacea is often described as having “types,” and you’ve probably seen different lists across different sources — sometimes 3 subtypes, sometimes 4, sometimes phenotypes instead of subtypes. Why the inconsistency? The terminology has evolved as researchers have understood that rosacea is more like a mosaic than a set of distinct boxes: most patients have features from multiple subtypes simultaneously, and the features can shift over time.

This article is the accessible explainer. If you want a deeper clinical-grade breakdown, see our complete Types of Rosacea guide which covers the latest classification consensus and treatment by feature.

At a glance

• The traditional classification names four subtypes — erythematotelangiectatic (ETR), papulopustular, phymatous, and ocular — but these overlap.
• Most patients have a primary pattern plus secondary features rather than a single clean subtype.
• The newer ROSCO consensus classifies rosacea by features (phenotypes) rather than subtypes, which better matches clinical reality.
• Knowing your dominant features matters because treatment differs: visible vessels respond to laser, bumps respond to topical antibiotics or anti-inflammatories, eye symptoms respond to ocular regimens.
• All subtypes share the same gentle skincare and trigger-management foundation.

1. Erythematotelangiectatic rosacea (ETR) — flushing and persistent redness

What it looks like: persistent redness across the central face (cheeks, nose, central forehead, chin), often with episodes of flushing on top of that baseline. Visible small blood vessels (telangiectasia) on the cheeks and around the nose are common with this subtype, especially over time. The skin frequently feels sensitive — burning, stinging, or tightness — even before products are applied.

Who tends to have it: ETR is the most common presenting pattern, particularly in fair-skinned adults. People who report “I flush easily” or “my skin has always been red” are usually describing ETR features.

What helps:

• Trigger management — sun, heat, alcohol, spicy food, stress (see our trigger guide)
• Daily mineral sunscreen (guide)
• Gentle barrier-supporting routine (guide)
• For visible vessels and persistent flushing: vascular laser (pulsed dye laser, KTP) or intense pulsed light (IPL)
• For acute redness: topical brimonidine (Mirvaso) or oxymetazoline (Rhofade) — vasoconstrictors that reduce redness for several hours

What’s less helpful: topical antibiotics (those are for the inflammatory bumps of papulopustular rosacea, not for redness alone). Oral antibiotics also don’t reliably help pure ETR.

2. Papulopustular rosacea — redness with acne-like bumps

What it looks like: alongside the redness, you also have inflammatory papules (small red bumps) and pustules (pus-filled bumps) on the central face. Crucially — and unlike acne — there are no comedones (no blackheads or whiteheads). The bumps are usually clustered on the cheeks, nose, chin, and forehead.

Who tends to have it: papulopustular rosacea often presents in adults aged 30-60. It’s frequently mistaken for adult acne, leading to inappropriate treatment with harsh acne products that can worsen the underlying rosacea.

What helps:

• The same gentle skincare and trigger-management foundation
• Topical prescriptions: ivermectin 1% cream (Soolantra), azelaic acid 15% gel/foam (Finacea), metronidazole 0.75-1% (MetroGel/MetroCream/MetroLotion). The Canadian Clinical Practice Guidelines for Rosacea (Asai et al., 2016) consider all three first-line options.
• Oral low-dose doxycycline (Oracea, 40 mg modified-release) for moderate-severe inflammatory rosacea. This dose is sub-antibacterial and works through anti-inflammatory effects rather than antibiotic action.
• For severe, refractory cases: oral isotretinoin at low doses, under specialist supervision.

What’s less helpful (and may worsen): acne products designed for sebum/comedone management — salicylic acid washes, benzoyl peroxide, scrubs. These can flare the underlying rosacea even if they temporarily reduce a specific bump.

3. Phymatous rosacea — skin thickening (often the nose)

What it looks like: progressive thickening, irregularity, and enlargement of skin in specific areas — most commonly the nose (rhinophyma), but also the chin (gnathophyma), forehead (metophyma), ears (otophyma), or eyelids (blepharophyma). Affected skin develops bumpy, irregular texture and may have visibly enlarged pores. Color often shifts toward a duller, sometimes purplish red.

Who tends to have it: phymatous changes develop later — typically age 50+, more often in men, more often in fair-skinned individuals. It’s rarer than the other subtypes but the most cosmetically distinctive when it does appear.

What helps:

• Early intervention with oral isotretinoin can slow phymatous progression in some cases
• For established phymatous changes, procedural treatment is the most effective: CO₂ laser resurfacing, electrosurgery, dermabrasion, or surgical reduction. These are dermatologic procedures performed by experienced clinicians.
• Continued rosacea management of inflammatory features even when phymatous changes dominate

What’s less helpful: topical-only management for established phymatous changes. Topicals can address concurrent inflammation but don’t reverse skin thickening.

For a deeper look at phymatous rosacea on the nose specifically, see our overview of rhinophyma.

4. Ocular rosacea — the most under-recognized subtype

What it looks like: eye involvement that often precedes or accompanies skin findings. Symptoms can include:

• Burning, stinging, or gritty sensation in the eyes
• Persistent dryness or tearing
• Red, bloodshot appearance, especially along the lid margins
• Recurrent styes (hordeolum) or chalazion
• Crusting along eyelashes; meibomian gland dysfunction
• Light sensitivity (photophobia)
• Blurry vision in severe cases

Who tends to have it: approximately half of all rosacea patients develop ocular features at some point, but the diagnosis is often missed because patients see different specialists for skin (dermatologist) and eyes (optometrist or ophthalmologist) without the connection being made.

What helps:

• Ocular hygiene: warm compresses to the closed eyelids (5-10 minutes daily), eyelid cleansing with diluted baby shampoo or commercial lid scrubs (e.g., OcuSoft, Avenova)
• Artificial tears (preservative-free for frequent use)
• Omega-3 fatty acids — modest evidence for symptom improvement
• Oral low-dose doxycycline is often more effective for ocular than topical-only treatment
• Cyclosporine eye drops or lifitegrast in moderate-severe ocular involvement
• Co-management with an ophthalmologist, especially if cornea is involved

Why it matters: untreated ocular rosacea can affect the cornea over time. The threshold for getting eye symptoms evaluated should be low.

Why people don’t fit cleanly into one type

If you’ve read this far and thought “I have features of two or three of these” — that’s normal and expected. The “subtype” framework is a useful teaching tool, but real-world rosacea is more about which features predominate at this moment in a particular patient.

The 2017 ROSCO (Rosacea Consensus) panel revised the classification toward a phenotype-based approach: rather than putting people in subtype boxes, clinicians identify which specific features are present and treat those features. This better matches what dermatologists actually see in clinic.

What this means practically: don’t fixate on which “type” you have. Identify which features bother you most (persistent redness? bumps? eye symptoms? visible vessels?) and treat those. Most rosacea management plans target multiple features in parallel.

The shared foundation across all types

Regardless of which features predominate, almost every rosacea-management plan includes:

• Daily broad-spectrum sunscreen (mineral preferred for reactive skin) — see mineral sunscreen guide
• Gentle, fragrance-free skincare routine — see routine guide
• Trigger awareness — see triggers article
• Avoidance of irritating ingredients — see ingredients to avoid
• Patience with treatment timelines — improvement happens over weeks, not days

On top of this shared foundation, treatment is layered based on which features are present.

When to see a dermatologist

The features that should prompt an evaluation rather than continued self-management:

• Eye symptoms — even mild ones. Ocular rosacea is undertreated.
• Inflammatory bumps that aren’t responding to gentle skincare alone
• Skin thickening on the nose — earlier intervention works better than later
• Severe flushing affecting daily life
• Visible vessels you’d like to address — vascular laser/IPL is the right tool
• Symptoms that are getting worse despite consistent gentle care

A dermatologist can confirm the diagnosis, rule out look-alikes (lupus, seborrheic dermatitis, perioral dermatitis), and prescribe the topical/oral treatments that go beyond what’s available over the counter.

Frequently asked questions

Can I have multiple subtypes at once?

Yes — and most people do. Having flushing, papules, AND mild eye symptoms simultaneously is a more common presentation than having one feature in isolation. The newer phenotype-based classification was designed to better capture this reality.

Can my rosacea subtype change over time?

Features can shift. Someone whose rosacea presents primarily as ETR in their 30s may develop more inflammatory papules in their 40s and phymatous changes in their 50s. This isn’t universal, but the trend toward additional features over time is well-documented.

How do I know if I have ocular rosacea?

If you have skin rosacea and persistent eye symptoms — burning, dryness, gritty feeling, recurrent styes, or chronic redness along the lid margins — ocular rosacea is plausible. The diagnosis is clinical and made by an eye-care professional. Tell both your dermatologist and your optometrist/ophthalmologist if you have rosacea and eye symptoms; they may not connect the dots otherwise.

Is rosacea on the cheeks different from rosacea on the nose?

Same condition, different skin sites. The cheeks tend to show ETR and papulopustular features more; the nose is the most common site of phymatous changes. Treatment approach varies based on which features predominate at each site.

Are rosacea subtypes inherited?

Susceptibility to rosacea has a genetic component — first-degree relatives of rosacea patients are more likely to have it themselves. Whether which subtype someone develops is also genetic isn’t well understood. Environmental factors (sun exposure, demodex density, lifestyle factors) clearly modify which features develop.

Can I prevent papulopustular rosacea from progressing to phymatous?

Possibly. Early treatment of inflammatory rosacea — particularly with oral isotretinoin in some cases — may reduce the risk of phymatous progression, though high-quality evidence for prevention specifically is limited. The current consensus is that good long-term inflammatory control is the best available preventive strategy.

What’s the difference between this article and the “Types of Rosacea” pillar guide?

This is the accessible introduction. The pillar guide goes deeper — into clinical classification systems (NRSEC vs ROSCO), severity grading, treatment algorithms by feature, and ocular sub-classification. If you want the full clinical picture, start there. If you want the plain-language overview, this is fine.

Does the rosacea subtype determine which products I should use?

Skincare-product choice is mostly the same across subtypes — gentle, fragrance-free, barrier-supporting, daily SPF. The subtype mostly determines which prescription treatments are most appropriate. Most rosacea-friendly OTC products work across subtypes.

Sources

• Asai Y, Tan J, Baibergenova A, et al. Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg 2016;20(5):432-45. PubMed PMID 27207355
• Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSCO panel. Br J Dermatol 2017;176(2):431-438. PubMed
• Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584-7. PubMed PMID 11907516
• American Academy of Dermatology — Rosacea: Signs and Symptoms
• National Rosacea Society — Subtypes and Variants

Educational content only — not medical advice. If you have eye symptoms, persistent inflammatory bumps, or skin thickening, see a dermatologist.